Here are relevant reports on : peptide-therapeutics-market
-
Medical Automation Market by Application (Diagnostics & Monitoring, Therapeutics, Lab & Pharmacy Automation, Medical Logistics & Training), End-User (Hospital, Diagnostic Center, Research Institute, Home/Ambulatory Care) - Global Forecast to 2020
The global medical automation market over the forecast period of 2015 to 2020. The market is expected to reach USD 55.03 Billion by 2020, at CAGR of 9.5% from 2015 to 2020. Continuous technological advancements in automation solutions, increasing government financial support for medical automation, rising labour costs, and growing need for reproducibility and accuracy are key factors fuelling the growth of the medical automation market. Increasing demand for automation in laboratories and pharmacies and high potential for early detection and treatment of diseases due to automation are some other prime factors offering growth opportunities for players in the medical automation market. However, high cost of automation is one of the key restraints for this market.
- Published: February 2016
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User – Global forecast to 2030
The global Microfluidics market, valued at US$23.71 billion in 2024, stood at US$24.96 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2030, culminating in a forecasted valuation of US$37.19 billion by the end of the period. Several significant factors are driving the growth of the microfluidics market, thereby enhancing its expansion and applications. There is a growing demand for point-of-care diagnostics, which require fast, accurate, and cost-effective instruments.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
US Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User [Hospital, Home Healthcare] Forecast to 2031
The US Medical Gas and Equipment Market, valued at USD 8.18 million in 2024, stood at USD 8.63 million in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2031, culminating in a forecasted valuation of USD 11.97 million by the end of the period. The growth of the medical gas and equipment market in US is primarily driven by the rising incidence of respiratory and chronic diseases, including COPD, asthma, cardiovascular disorders, and sleep apnea, as well as a rapidly aging population that requires long-term oxygen therapy and critical care support.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
US Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase)- Forecast to 2031
The US pen needles market, valued at US$0.85 billion in 2025, stood at US$0.93 billion in 2026 and is projected to advance at a resilient CAGR of 10.4% from 2026 to 2031, culminating in a forecasted valuation of US$1.53 billion by the end of the period.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030
The global pen needles market, valued at US$1.69B in 2023, is forecasted to grow at a 9.2% CAGR, reaching US$1.81B by 2024 and US$3.08B by 2030. The key factors driving the market growth of the pen needles market include the rising incidence of chronic diseases, favorable reimbursements in certain countries, and decreasing prices of insulin formulations. Factors that provide opportunities for market players include the growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
Europe Pen Needles Market By Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase) - Forecast to 2031
Europe Pen Needles market, valued at US$0.66 billion in 2025, stood at US$0.72 billion in 2026 and is projected to advance at a resilient CAGR of 8.9% from 2026 to 2031, culminating in a forecasted valuation of US$1.10 billion by the end of the period. The Europe pen needles market is propelled by soaring rate of diabetes prevalence, growing numbers of older adults, high levels of obesity, augmented uptake of insulin and GLP-1 pens leading to increased per-patient needle usage.
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Adipose Derived Stem Cell Market by Type (Autologous, Allogeneic), Product (Cell Line. Culture Media), Disease (CVS, CNS, MSK, Obesity, Cancer), End User (Hospitals, Tissue Banks, Academia), Application (Therapeutics, Research) - Global Forecasts to 2019
Emerging markets including China, India, South Korea, and Brazil have become attractive destinations for companies engaged in the development and manufacturing of adipose derived stem cell products. A number of factors such as growing preference for use of adipose derived stem cells in therapeutics and emerging markets offering low regulatory barriers for conducting clinical studies are offering new growth opportunities for players active in the global adipose derived stem cell market
- Published: May 2026
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
